Genomic Prediction, based in North Brunswick, NJ, is a leading brand that specializes in advanced genetic screening for IVF embryos. Their flagship product, LifeView™ PGT, offers the most advanced technology in the field. Extensive studies have shown that LifeView outperforms conventional testing methods, resulting in higher pregnancy rates and lower miscarriage rates.

The brand offers a range of tests to meet different needs. PGT-A is a routine screening that determines if an embryo has the correct number of chromosomes. PGT-A+ goes further by determining the origin of an embryo's chromosome abnormality.

PGT-M is designed for parents with an increased risk of passing monogenic disorders to their children. Genomic Prediction also provides the Embryo Health Score (PGT-P) test, which reduces disease risk for future children, including heart disease, cancer, and diabetes. PGT-SR screens for chromosome abnormalities caused by known structural rearrangements in parents, while the M2 test screens biological parents for a gene associated with increased miscarriage risk.

For prospective parents, Genomic Prediction aims to be a part of their journey, offering support and expertise. Clinicians can easily partner with the brand to improve patient outcomes. With a mission to enhance the success of IVF through innovation and rigorous validation, Genomic Prediction is committed to providing the most comprehensive genetic analysis of the preimplantation embryo available today.

Contact Genomic Prediction at their North Brunswick address or through their website to learn more about their cutting-edge services